Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
| Status: | Archived |
|---|---|
| Conditions: | Sinusitis, Pulmonary |
| Therapuetic Areas: | Otolaryngology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
The Use of Nasally Delivered Pulmozyme in the Treatment of Sinusitis in Cystic Fibrosis Patients: A Pilot Study
Chronic sinusitis is a frequent complication in cystic fibrosis. The aim of this study is to
determine whether Pulmozyme(dornase alfa) would maintain sinus health (compared to placebo)
in patients with cystic fibrosis who have recently undergone sinus surgery.
AIM: To evaluate the effectiveness of Pulmozyme(dornase alfa) in decreasing post-operative
sinusitis symptoms in patients with cystic fibrosis
PROCEDURES: 20 patients with CF will be randomized to receive either Pulmozyme or placebo
via nasal inhalation daily for 12 months. Consent will be obtained following surgery and
treatment will begin 1 week post-operatively.
Monitoring will include examination and recording of adverse effects and follow up weekly
for one month and then at 2.5, 6, 9 and 12 months.
Outcome measures will include ciliary function testing, pulmonary function testing, sinus
questionnaires and CT scan.
We found this trial at
1
site
Fletcher Allen Health Care As Vermont’s University Medical Center, we at Fletcher Allen are committed...
Click here to add this to my saved trials
